Shares of FANGZHOU JIANKE (06086) surged 9.12% in Monday's trading session, as investors reacted positively to the company's strong 2025 interim results and its strategic positioning in the AI-powered chronic disease management sector.

The company's financial report, released on August 27, showcased impressive growth and a significant turnaround in profitability. FANGZHOU JIANKE reported revenue of approximately RMB 1.494 billion for the first half of 2025, representing a 12.9% year-on-year increase. More notably, the company achieved a net profit of RMB 12.5 million, marking a shift from loss to profit. The adjusted net profit also saw a 16.8% year-on-year increase to approximately RMB 17.6 million, reaching a historical high.

Investors were particularly encouraged by FANGZHOU JIANKE's strong user metrics and its innovative "AI+H2H" (AI+Hospital To Home) ecosystem. The company's registered user base grew to 52.8 million, up 15.8% year-on-year, while monthly active users surged by 34.4% to 11.9 million. The high user retention rate of 85.4% for paid users underscores the effectiveness of the company's "familiar doctor-patient" model in creating a sticky ecosystem. Furthermore, FANGZHOU JIANKE's strategic focus on AI-driven solutions for chronic disease management positions it well in a market expected to reach RMB 2,471.2 billion by 2033, according to Frost & Sullivan data.

The market's enthusiastic response also reflects growing confidence in FANGZHOU JIANKE's long-term potential. Citi recently initiated coverage of the stock with a "Buy" rating and a target price of HK$8.5, suggesting significant upside potential. As the company continues to leverage AI technology to enhance its chronic disease management platform and expand its partnerships with pharmaceutical companies and insurance providers, it appears well-positioned to capitalize on the growing demand for efficient and accessible healthcare solutions in China's aging population.